HTA and EU JCA submissions
The submission is where the evidence meets the decision. We write and assemble dossiers that answer the assessor's questions directly and hold together from clinical section to economic case.
Our work is built for the bodies that decide: NICE, G-BA, HAS, CDA-AMC, US payers and the EU Joint Clinical Assessment.
For Europe, we support the full JCA process: predicting the PICO scope, planning the analyses each PICO needs, and preparing the dossier within the fixed timelines. Our EU JCA page walks through each step.
What we deliver
- HTA submission dossiers
- EU JCA dossiers
- PICO scoping and simulation
- JCA readiness assessments
- Responses to assessor questions
- Reimbursement and formulary submissions
Related publications from our team
The EU JCA, step by step
See how PICO scoping, consolidation, evidence synthesis and the dossier fit together on our EU JCA page.
Common questions
What is the EU Joint Clinical Assessment?
The Joint Clinical Assessment is a single EU-level assessment of a new treatment's relative clinical effectiveness and safety, introduced by the EU HTA Regulation (EU) 2021/2282. It has applied to new cancer medicines and advanced therapy medicinal products since January 2025, extends to orphan medicines in 2028, and to all new centrally authorised medicines from 2030. Member States use the report in their own pricing and reimbursement decisions.
What is PICO scoping?
Joint Clinical Assessments are scoped using PICOs: the populations, interventions, comparators and outcomes that Member States want assessed. PICO scoping predicts that scope in advance so you can prepare evidence for each likely question.
Patients should not be left waiting for treatments that can change their lives.
We are committed to a healthcare system where value is measured fairly and decisions are guided by sound evidence. Tell us what you are working on and we will show you how we would approach it.
